Citadel Advisors LLC Invests $42,000 in Bolt Biotherapeutics, Inc. (NASDAQ:BOLT)

Citadel Advisors LLC bought a new position in Bolt Biotherapeutics, Inc. (NASDAQ:BOLT - Free Report) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund bought 78,961 shares of the company's stock, valued at approximately $42,000. Citadel Advisors LLC owned about 0.21% of Bolt Biotherapeutics as of its most recent SEC filing.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on the stock. Stifel Nicolaus decreased their price target on shares of Bolt Biotherapeutics from $25.00 to $20.00 and set a "hold" rating for the company in a report on Tuesday, May 13th. Lake Street Capital began coverage on Bolt Biotherapeutics in a research note on Tuesday, May 20th. They set a "buy" rating and a $80.00 price objective on the stock. Finally, HC Wainwright reaffirmed a "neutral" rating on shares of Bolt Biotherapeutics in a research report on Tuesday, March 25th.

Bolt Biotherapeutics Trading Down 4.6%

Shares of BOLT stock traded down $0.30 during mid-day trading on Thursday, hitting $6.23. The company's stock had a trading volume of 17,526 shares, compared to its average volume of 10,609. The company has a market cap of $11.94 million, a PE ratio of -3.64 and a beta of 0.91. Bolt Biotherapeutics, Inc. has a 52 week low of $5.20 and a 52 week high of $15.60. The company's fifty day simple moving average is $6.75 and its 200-day simple moving average is $8.89. The company has a debt-to-equity ratio of 0.21, a quick ratio of 3.16 and a current ratio of 3.16.

Bolt Biotherapeutics (NASDAQ:BOLT - Get Free Report) last released its quarterly earnings results on Monday, May 12th. The company reported ($5.80) earnings per share for the quarter, topping the consensus estimate of ($6.80) by $1.00. Bolt Biotherapeutics had a negative net margin of 665.56% and a negative return on equity of 69.46%. The business had revenue of $1.22 million for the quarter, compared to analysts' expectations of $0.77 million. As a group, equities research analysts expect that Bolt Biotherapeutics, Inc. will post -1.61 earnings per share for the current fiscal year.

Bolt Biotherapeutics Company Profile

Bolt Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer. The company's lead product candidate BDC-1001, which is in clinical development for the treatment of patients with human epidermal growth factor receptor 2- positive solid tumors, including breast, colorectal, endometrial, and gastroesophageal cancer.